Clinical Trials Browser

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT05241340 2025-10-24

RAD-VACCINE

Phase 2 Active not recruiting

33 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

NCT06325046 2025-10-16

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

Phase NA Recruiting

144 enrolled

Genitourinary

Prostatic Neoplasms

NCT03693014 2025-10-06

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Phase 2 Active not recruiting

69 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT06320067 2025-09-26

STAMPEDE2

Phase 3 Recruiting

3,360 enrolled

Genitourinary

Prostate Cancer Metastatic

NCT07189598 2025-09-24

ORION

Phase NA Not yet recruiting

390 enrolled

Genitourinary

Prostatic Neoplasms

NCT02170181 2025-09-17

Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation

Completed

149 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Lung Neoplasms, Prostatic Neoplasms

NCT03889119 2025-09-15

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Phase NA Active not recruiting

100 enrolled

Genitourinary

Prostatic Neoplasms

NCT01655836 2025-09-11

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Phase 1 Active not recruiting

42 enrolled

Genitourinary

Prostatic Neoplasms

NCT06927635 2025-09-05

SECURE

Phase 2 Recruiting

75 enrolled

Genitourinary

Castrate Resistance Prostate Cancer

NCT02470897 2025-09-04

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

Phase NA Completed

115 enrolled

Genitourinary

Stage I Prostate Adenocarcinoma

Clinical Trials

GARUDA

STEREOBED

PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.

SHARP

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

PRO-BOOST-LC

METRO

A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer

REVELUTION

Focal Radiotherapy for Previously Treated Prostate Cancer Patients

ARPEGGIO

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

SBRT Boost for Unfavorable Prostate Cancer'

PROMPT

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

SOAR

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

PILLAR

Prospective Observational Trial of Image-guided Ablative STereotactic bOdy Radiation Therapy for Primary kidNey Cancer: the STONE Trial

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

STROKER

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

DIVINE

SBRTRC

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma

LUST

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

DE-CART

Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

RAD-VACCINE

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

STAMPEDE2

ORION

Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

SECURE

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer